Chimeric SV40 virus-like particles induce specific cytotoxicity and protective immunity against influenza A virus without the need of adjuvants

Virology

Volumn 448, Issue , 2014, Pages 159-167

  Kawano, Masaaki ^a   Morikawa, Katsuma ^b   Suda, Tatsuya ^a,c   Ohno, Naohito ^c   Matsushita, Sho ^a   Akatsuka, Toshitaka ^a   Handa, Hiroshi ^b   Matsui, Masanori ^a  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

^b TOKYO INSTITUTE OF TECHNOLOGY   (Japan)

^c TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES   (Japan)

Author keywords

Adjuvant; Cytotoxic T lymphocyte; Influenza A virus; Polyomavirus; SV40; Vaccine; Virus like particles

Indexed keywords

ADJUVANT; DEOXYRIBONUCLEASE I; EPITOPE; FMP 58 66 EPITOPE; HLA A ANTIGEN; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG; VIRUS LIKE PARTICLE VACCINE; VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELLULAR IMMUNITY; CHIMERA; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; GENE CONSTRUCT; IMMUNIZATION; IMMUNOLOGICAL MEMORY; INFLUENZA VIRUS A; MOUSE; NONHUMAN; POLYOMA VIRUS; PRIORITY JOURNAL; SIMIAN VIRUS 40; TRANSGENIC MOUSE; VIRUS LIKE AGENT;

EID: 84886411258     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2013.10.010     Document Type: Article

References (55)

1. Amara R.R., Villinger F., Altman J.D., Lydy S.L., O'Neil S.P., Staprans S.I., Montefiori D.C., Xu Y., Herndon J.G., Wyatt L.S., Candido M.A., Kozyr N.L., Earl P.L., Smith J.M., Ma H.L., Grimm B.D., Hulsey M.L., Miller J., McClure H.M., McNicholl J.M., Moss B., Robinson H.L. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 2001, 292:69-74.
2. Belyakov I.M., Moss B., Strober W., Berzofsky J.A. Mucosal vaccination overcomes the barrier to recombinant vaccinia immunization caused by preexisting poxvirus immunity. Proceedings of the National Academy of Sciences of the United States of America 1999, 96:4512-4517.
3. Boura E., Liebl D., Spisek R., Fric J., Marek M., Stokrova J., Holan V., Forstova J. Polyomavirus EGFP-pseudocapsids: analysis of model particles for introduction of proteins and peptides into mammalian cells. FEBS Letters 2005, 579:6549-6558.
4. Buonaguro L., Racioppi L., Tornesello M.L., Arra C., Visciano M.L., Biryahwaho B., Sempala S.D., Giraldo G., Buonaguro F.M. Induction of neutralizing antibodies and cytotoxic T lymphocytes in Balb/c mice immunized with virus-like particles presenting a gp120 molecule from a HIV-1 isolate of clade A. Antiviral Research 2002, 54:189-201.
5. Butel J.S., Lednicky J.A. Cell and molecular biology of simian virus 40: implications for human infections and disease. Journal of the National Cancer Institute 1999, 91:119-134.
6. Campo M.S., Roden R.B. Papillomavirus prophylactic vaccines: established successes, new approaches. Journal of Virology 2010, 84:1214-1220.
7. Ding F.X., Wang F., Lu Y.M., Li K., Wang K.H., He X.W., Sun S.H. Multiepitope peptide-loaded virus-like particles as a vaccine against hepatitis B virus-related hepatocellular carcinoma. Hepatology 2009, 49:1492-1502.
8. Eriksson M., Andreasson K., Weidmann J., Lundberg K., Tegerstedt K., Dalianis T., Ramqvist T. Murine polyomavirus virus-like particles carrying full-length human PSA protect BALB/c mice from outgrowth of a PSA expressing tumor. PLoS One 2011, 6:e23828.
9. Ewers H., Romer W., Smith A.E., Bacia K., Dmitrieff S., Chai W., Mancini R., Kartenbeck J., Chambon V., Berland L., Oppenheim A., Schwarzmann G., Feizi T., Schwille P., Sens P., Helenius A., Johannes L. GM1 structure determines SV40-induced membrane invagination and infection. Nature Cell Biology 2010, 12:11-18.
10. Goldmann C., Petry H., Frye S., Ast O., Ebitsch S., Jentsch K.D., Kaup F.J., Weber F., Trebst C., Nisslein T., Hunsmann G., Weber T., Luke W. Molecular cloning and expression of major structural protein VP1 of the human polyomavirus JC virus: formation of virus-like particles useful for immunological and therapeutic studies. Journal of Virology 1999, 73:4465-4469.
11. Gotch F., Rothbard J., Howland K., Townsend A., McMichael A. Cytotoxic T lymphocytes recognize a fragment of influenza virus matrix protein in association with HLA-A2. Nature 1987, 326:881-882.
12. Greenstone H.L., Nieland J.D., de Visser K.E., De Bruijn M.L., Kirnbauer R., Roden R.B., Lowy D.R., Kast W.M., Schiller J.T. Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model. Proceedings of the National Academy of Sciences of the United States of America 1998, 95:1800-1805.
13. Herbst-Kralovetz M., Mason H.S., Chen Q. Norwalk virus-like particles as vaccines. Expert Review of Vaccines 2010, 9:299-307.
14. Hilleman M.R. Discovery of simian virus 40 (SV40) and its relationship to poliomyelitis virus vaccines. Developments in Biological Standardization 1998, 94:183-190.
15. Houghton M., Abrignani S. Prospects for a vaccine against the hepatitis C virus. Nature 2005, 436:961-966.
16. Inoue T., Kawano M., Takahashi R., Tsukamoto H., Enomoto T., Imai T, Kataoka K., Handa H. Engineering of SV40-based nano-capsules for delivery of heterologous proteins as fusions with the monor capsid proteins VP2/3. Journal of Biotechnology 2008, 134:181-192.
17. Ishizu K.I., Watanabe H., Han S.I., Kanesashi S.N., Hoque M., Yajima H., Kataoka K., Handa H. Roles of disulfide linkage and calcium ion-mediated interactions in assembly and disassembly of virus-like particles composed of simian virus 40 VP1 capsid protein. Journal of Virology 2001, 75:61-72.
18. Kang S.M., Yoo D.G., Lipatov A.S., Song J.M., Davis C.T., Quan F.S., Chen L.M., Donis R.O., Compans R.W. Induction of long-term protective immune responses by influenza H5N1 virus-like particles. PLoS One 2009, 4:e4667.
19. Kawano M., Matsui M., Handa H. SV40 virus-like particles as an effective delivery system and its application to a vaccine carrier. Expert Review of Vaccines 2013, 12:199-210.
20. Kosukegawa A., Arisaka F., Takayama M., Yajima H., Kaidow A., Handa H. Purification and characterization of virus-like particles and pentamers produced by the expression of SV40 capsid proteins in insect cells. Biochimica et Biophysica Acta 1996, 1290:37-45.
21. Koup R.A., Douek D.C. Vaccine design for CD8 T lymphocyte responses. Cold Spring Harbor Perspectives in Medicine 2011, 1:a007252.
22. Lacasse P., Denis J., Lapointe R., Leclerc D., Lamarre A. Novel plant virus-based vaccine induces protective cytotoxic T-lymphocyte-mediated antiviral immunity through dendritic cell maturation. Journal of Virology 2008, 82:785-794.
23. Lenz P., Day P.M., Pang Y.Y., Frye S.A., Jensen P.N., Lowy D.R., Schiller J.T. Papillomavirus-like particles induce acute activation of dendritic cells. Journal of Immunology 2001, 166:5346-5355.
24. Liu M.A. Immunologic basis of vaccine vectors. Immunity 2010, 33:504-515.
25. Liu W.J., Liu X.S., Zhao K.N., Leggatt G.R., Frazer I.H. Papillomavirus virus-like particles for the delivery of multiple cytotoxic T cell epitopes. Virology 2000, 273:374-382.
26. Lutz M.B., Kukutsch N., Ogilvie A.L., Rossner S., Koch F., Romani N., Schuler G. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. Journal of Immunological Methods 1999, 223:77-92.
27. Marrack P., McKee A.S., Munks M.W. Towards an understanding of the adjuvant action of aluminium. Nature Reviews Immunology 2009, 9:287-293.
28. *0201 transgenic mice. Biochemical and Biophysical Research Communications 2010, 391:1494-1499.
29. Matsui M., Moriya O., Abdel-Aziz N., Matsuura Y., Miyamura T., Akatsuka T. Induction of hepatitis C virus-specific cytotoxic T lymphocytes in mice by immunization with dendritic cells transduced with replication-defective recombinant adenovirus. Vaccine 2002, 21:211-220.
30. Matsui M., Moriya O., Yoshimoto T., Akatsuka T. T-bet is required for protection against vaccinia virus infection. Journal of Virology 2005, 79:12798-12806.
31. Mazeike E., Gedvilaite A., Blohm U. Induction of insert-specific immune response in mice by hamster polyomavirus VP1 derived virus-like particles carrying LCMV GP33 CTL epitope. Virus Research 2012, 163:2-10.
32. McMichael A.J., Borrow P., Tomaras G.D., Goonetilleke N., Haynes B.F. The immune response during acute HIV-1 infection: clues for vaccine development. Nature Reviews Immunology 2010, 10:11-23.
33. Neijssen J., Herberts C., Drijfhout J.W., Reits E., Janssen L., Neefjes J. Cross-presentation by intercellular peptide transfer through gap junctions. Nature 2005, 434:83-88.
34. O'Hagan D.T., Ott G.S., De Gregorio E., Seubert A. The mechanism of action of MF59 - an innately attractive adjuvant formulation. Vaccine 2012, 30:4341-4348.
35. Oka Y., Tsuboi A., Oji Y., Kawase I., Sugiyama H. WT1 peptide vaccine for the treatment of cancer. Current Opinion in Immunology 2008, 20:211-220.
36. Pascolo S., Bervas N., Ure J.M., Smith A.G., Lemonnier F.A., Perarnau B. HLA-A2.1-restricted education and cytolytic activity of CD8(+) T lymphocytes from beta2 microglobulin (beta2m) HLA-A2.1 monochain transgenic H-2Db beta2m double knockout mice. Journal of Experimental Medicine 1997, 185:2043-2051.
37. Pejawar-Gaddy S., Rajawat Y., Hilioti Z., Xue J., Gaddy D.F., Finn O.J., Viscidi R.P., Bossis I. Generation of a tumor vaccine candidate based on conjugation of a MUC1 peptide to polyionic papillomavirus virus-like particles. Cancer Immunology and Immunotherapy 2010, 59:1685-1696.
38. Qi F., Carbone M., Yang H., Gaudino G. Simian virus 40 transformation, malignant mesothelioma and brain tumors. Expert Review of Respiratory Medicine 2011, 5:683-697.
39. Qian J., Dong Y., Pang Y.Y., Ibrahim R., Berzofsky J.A., Schiller J.T., Khleif S.N. Combined prophylactic and therapeutic cancer vaccine: enhancing CTL responses to HPV16 E2 using a chimeric VLP in HLA-A2 mice. International Journal of Cancer 2006, 118:3022-3029.
40. Roy P., Noad R. Virus-like particles as a vaccine delivery system: myths and facts. Human Vaccines 2008, 4:5-12.
41. Sadeyen J.-R.É., Tourne S., Shkreli M., Sizaret P.-Y., Coursaget P. Insertion of a foreign sequence on capsid surface loops of human papillomavirus type 16 virus-like particles reduces their capacity to induce neutralizing antibodies and delineates a conformational neutralizing epitope. Virology 2003, 309:32-40.
42. Schell T.D., Lippolis J.D., Tevethia S.S. Cytotoxic T lymphocytes from HLA-A2.1 transgenic mice define a potential human epitope from simian virus 40 large T antigen. Cancer Research 2001, 61:873-879.
43. Shiver J.W., Emini E.A. Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors. Annual Review of Medicine 2004, 55:355-372.
44. Skeiky Y.A., Sadoff J.C. Advances in tuberculosis vaccine strategies. Nature Reviews Microbiology 2006, 4:469-476.
45. Storni T., Ruedl C., Schwarz K., Schwendener R.A., Renner W.A., Bachmann M.F. Nonmethylated CG motifs packaged into virus-like particles induce protective cytotoxic T cell responses in the absence of systemic side effects. Journal of Immunology 2004, 172:1777-1785.
46. Suda T., Kawano M., Nogi Y., Ohno N., Akatsuka T., Matsui M. The route of immunization with adenoviral vaccine influences the recruitment of cytotoxic T lymphocytes in the lung that provide potent protection from influenza A virus. Antiviral Research 2011, 91:252-258.
47. Sun C., Feng L., Zhang Y., Xiao L., Pan W., Li C., Zhang L., Chen L. Circumventing antivector immunity by using adenovirus-infected blood cells for repeated application of adenovirus-vectored vaccines: proof of concept in rhesus macaques. Journal of Virology 2012, 86:11031-11042.
48. Sutter G., Moss B. Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proceedings of the National Academy of Sciences of the United States of America 1992, 89:10847-10851.
49. Takahashi R.U., Kanesashi S.N., Inoue T., Enomoto T., Kawano M.A., Tsukamoto H., Takeshita F., Imai T., Ochiya T., Kataoka K., Yamaguchi Y., Handa H. Presentation of functional foreign peptides on the surface of SV40 virus-like particles. Journal of Biotechnology 2008, 135:385-392.
50. Tegerstedt K., Franzen A., Ramqvist T., Dalianis T. Dendritic cells loaded with polyomavirus VP1/VP2Her2 virus-like particles efficiently prevent outgrowth of a Her2/neu expressing tumor. Cancer Immunology and Immunotherapy 2007, 56:1335-1344.
51. Tegerstedt K., Lindencrona J.A., Curcio C., Andreasson K., Tullus C., Forni G., Dalianis T., Kiessling R., Ramqvist T. A single vaccination with polyomavirus VP1/VP2Her2 virus-like particles prevents outgrowth of HER-2/neu-expressing tumors. Cancer Research 2005, 65:5953-5957.
52. Tsai B., Gilbert J.M., Stehle T., Lencer W., Benjamin T.L., Rapoport T.A. Gangliosides are receptors for murine polyoma virus and SV40. EMBO Journal 2003, 22:4346-4355.
53. Wakim L.M., Bevan M.J. Cross-dressed dendritic cells drive memory CD8+ T-cell activation after viral infection. Nature 2011, 471:629-632.
54. Win S.J., Ward V.K., Dunbar P.R., Young S.L., Baird M.A. Cross-presentation of epitopes on virus-like particles via the MHC I receptor recycling pathway. Immunology and Cell Biology 2011, 89:681-688.
55. Young S.L., Wilson M., Wilson S., Beagley K.W., Ward V., Baird M.A. Transcutaneous vaccination with virus-like particles. Vaccine 2006, 24:5406-5412.